Why did AI discuss Leronlimab and a different rece
Post# of 153889
(Total Views: 396)
Posted On: 05/22/2025 12:29:42 PM
Why did AI discuss Leronlimab and a different receptor CXCR4?? The company X4 Pharm, ticker XFOR, has a drug that inhibits CXCR4. First they chased clear cell renal cell carcinoma. Now "focusing" on rare/ultra-rare diseases. Buy CYDY, not this one. IMO and experience.
(6)
(0)